Research ArticleCancer

Metabolic Modulation of Glioblastoma with Dichloroacetate

See allHide authors and affiliations

Science Translational Medicine  12 May 2010:
Vol. 2, Issue 31, pp. 31ra34
DOI: 10.1126/scitranslmed.3000677

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

  • Re:Adding Credence to Clear Treatments

    I self medicated with DCA for 18 months with no other chemo or radiation, nothing but some supplements that I added over the 18 months.

    Added Metformin near the end. The first four months my Hylar CRC metastatic tumor shrunk 70% and then stayed stable for 14 months.

    I am now on Folfiri and Avastin. I was followed during this DCA period at a major cancer hospital.

    Now I am interested in tryin...

    Show More
    Competing Interests: None declared.
  • Adding Credence to Clear Treatments

    Glioblastoma multiforme (GBM) is a notoriously aggressive form of cancer. Its prognosis remains poor and little advancement in treatment strategy has emerged in the last decade. However, the recent report of clinical trials conducted by the group of Evangelos Michelakis (1) gives hope to GBM sufferers. With this publication, it is hoped that the use of dichloroacetate (DCA) will gain wider acceptance in the oncology com...

    Show More
    Competing Interests: None declared.